Advances in Pharmacotherapy for Nasal Disorders in Rhinology
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (30 September 2025) | Viewed by 2596
Special Issue Editor
Interests: otorhinolaryngology; rhinology; pediatric diseases; molecular medicine; biologics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the last decade, precision medicine and new biologics have revolutionized clinical practice. Every day we face new therapeutic challenges that require a meticulous selection process. This Special Issue aims to provide readers and colleagues with several new therapeutic strategies for the treatment of sinonasal diseases in adults and children. Chronic rhinosinusitis is a widespread and challenging disease affecting about 5% to 12% of the general population, exerting a significant social and economic impact. Depending on the presence or absence of nasal polyps, CRS is divided into two subgroups: chronic rhinosinusitis without nasal polyps and chronic rhinosinusitis with nasal polyps. The latter is an inflammatory disease predominantly driven by type 2 inflammation, which is characterized by the upregulation of type 2 cytokines interleukin (IL)-4, IL-13, and IL-5, high concentrations of tissue immunoglobulin (Ig)E, and increased serum IgE. T2 inflammation has been described as a common pathophysiological basis of chronic rhinosinusitis with nasal polyps and several comorbidities such as asthma, allergic rhinitis, atopic dermatitis, etc., which often coexist in the same patient.
Chronic rhinosinusitis is characterized by chronic inflammation in the paranasal sinus, with persistent and debilitating symptoms that include nasal obstruction, hyposmia, or anosmia. Persistent symptoms have a strong negative impact on the patient’s quality of life and productivity compared to other serious chronic diseases. Chronic rhinosinusitis in children is a common condition that is often misdiagnosed and can be challenging to treat. The exact prevalence of pediatric rhinosinusitis is unknown because only a small percentage of cases present to the physician’s office. It is estimated that 6% to 13% of children will have had an episode of rhinosinusitis by 3 years of age.
Pediatric chronic rhinosinusitis can be difficult to accurately diagnose, given multiple possible contributing factors and varying symptoms that can be challenging to ascertain in children. Studies of pediatric chronic rhinosinusitis often focus on select populations of patients with upper respiratory complaints. Comorbidities associated with chronic rhinosinusitis should be carefully assessed in everyday clinical practice, even with the help of new diagnostic technologies, artificial intelligence, and multidisciplinary teams. With the perspective of precision medicine and a multidisciplinary approach, this Special Issue aims to describe not only the new challenges in clinical diagnostics but also to provide therapeutic tools useful in clinical practice to personalize strategies from a patient-centered perspective. Furthermore, the need for an integrated multidisciplinary approach in the evaluation of diseases in the fields of rhinology, otology, laryngology, allergology, immunology, pulmonology, pediatrics, dermatology, gastroenterology, and more cannot be overlooked.
These are the reasons that I proposed this Special Issue to collect articles on "Advances in Pharmacotherapy for Nasal Disorders in Rhinology". Studies should describe the challenges and perspectives in rhinology diagnostics and therapy using basic science, clinical, and population-based approaches.
Dr. Elena Cantone
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- rhinology
- CRS
- asthma
- nasal polyps
- biologics
- airflow
- children
- QoL
- artificial intelligence
- olfaction
- chemical senses
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
